Liflex Science
RNA-based therapeutics for degenerative arthritis treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Seed | |
| Total Funding | 000k | ||
Liflex Science is a biotechnology company established in 2021, focusing on the development of RNA-based treatments for degenerative arthritis. The company is headquartered in Seoul, South Korea, and operates within the biopharmaceutical sector.
The firm's primary objective is to provide a cure for degenerative arthritis through its ribonucleic acid (RNA) therapeutic platform. By targeting the underlying mechanisms of the disease, Liflex aims to offer a more effective solution compared to traditional treatments. The business model centers on the research, development, and eventual commercialization of these novel drug candidates. Its clients would include patients suffering from degenerative arthritis and healthcare providers, operating in the global pharmaceutical and healthcare markets.
Liflex Science has secured investments from entities such as RP Bio and Seoul National University Technology Holdings, which supports its research and development activities. The company was founded by individuals with backgrounds in science and technology, although specific details about their professional journeys are not publicly available. The founding team includes Fahad Azam, Fathi Ghorbel, Shengda Ding, and Zohreh M. Hashemi.
Keywords: RNA therapeutics, degenerative arthritis, biotechnology, biopharmaceutical, joint disease, drug development, medical research, orthopedics, life sciences, Seoul, South Korea, molecular therapy, healthcare innovation, RP Bio, Seoul National University Technology Holdings, genetic medicine, ribonucleic acid, joint health, cartilage degeneration, therapeutic solutions